
Sign up to save your podcasts
Or


In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt’s disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio’s mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio’s clinical trials. Learn more here:
www.splice.bio/clinical
Or send an email to:
#SpliceBio #genetherapy #clinicaltrials
By Sam Seavey4.9
1919 ratings
In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt’s disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio’s mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio’s clinical trials. Learn more here:
www.splice.bio/clinical
Or send an email to:
#SpliceBio #genetherapy #clinicaltrials

91,173 Listeners

43,722 Listeners

35 Listeners

16 Listeners

48 Listeners

25,862 Listeners

87,740 Listeners

24,652 Listeners

1 Listeners

28 Listeners

9,478 Listeners

1 Listeners

15 Listeners

4,612 Listeners